Abstract
Experimental hyperthyroidism had a negative effect on bone mineral density, but did not significantly alter mechanical properties of femur and femoral bone thickness. Estradiol at a dose used in humans for the treatment of osteoporosis decreased seminal vesicle weight and concentration of testosterone but increased bone density in male rats compared to intact animals. In these rats, the mechanical analysis revealed an increased mechanical femur strength higher than the increase in bone density and femoral cortical thickness. When hyperthyroid male rats with low bone density were treated with estradiol in spite of a low plasma testosterone, the changes in bone density resulting from hyperthyroidism were entirely prevented. Estrogens protect the male skeleton against resorbing action of T3. Treatment with estradiol in male rats with hyperthyroidism did not increase mechanical bone strength or femoral cortical thickness as it did with estradiol administration alone. Our results suggest that exogenously administered estrogens may have therapeutic value in preventing bone loss accompanying triiodothyronine administration, even in male rats with a low testosterone levels. At the concentration studied, estradiol increased in spite of low plasma testosterone, bone mineral density, mechanical strength of femur, and femoral cortical thickness.
Key words
Hyperthyroidism - Bone Mineral Density - Mechanical Strength - Estradiol - Male Rats
References
-
1
Mosekilde L, Eriksen E F, Charles P.
Effects of thyroid hormones on bone and mineral metabolism.
Endocrinol Metab Clin North Am.
1990;
19
35-63
-
2
Broulik P D, Steˇpán J.
Bone isoenzyme of serum alkaline phosphatase and urinary hydroxyproline. excretion in thyrotoxicosis.
Endocrinologia Exp.
1985;
19
165-169
-
3
Pantazi H, Papapetrou P D.
Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism.
J Clin Endocrinol Metab.
2000;
85
1099-1106
-
4
di Pippo V A, Lindsay R, Powers C A.
Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized, thyroidectomized rat.
Endocrinology.
1995;
136
1020-1033
-
5
Orwell E S, Nelson H D.
Does estrogen adequately protect postmenopausal women against osteoporosis: An iconoclastic perspective.
J Clin Endocrinol Metab.
1999;
84
1872-1874
-
6
Gomez J M, Gomez N, Fiter J, Soler J.
Effects of long term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.
Horm Metab Res.
2000;
32
66-70
-
7
Seeman E.
Pathogenesis of bone fragility in women and men.
Lancet.
2002;
359
1841-1850
-
8
Fitts J M, Klein R M, Powers C A.
Estrogen and tamoxifen interplay with T3 in male rats: pharmacologically distinct classes of estrogen responses affecting growth, bone, and lipid metabolism and their relation to serum GH and IGF 1.
Endocrinology.
2001;
142
4223-4235
-
9
Kalu D N, Hardin R R, Cockerham R.
Evaluation of the pathogenesis of skeletal changes in ovariectomized rats.
Endocrinology.
1994;
115
507-511
-
10
Gitelman H J.
An improved automated procedure for the determination of calcium in biological specimens.
Anal Biochem.
1967;
18
521-531
-
11
Kraml J.
A semiautomated determination of phospholipids.
Clin Chim Acta.
1966;
13
442- 448
-
12
Beall P T, Misra L K, Young R L, Spjut H J, Evans H J, Le Blame A.
Clomiphene protects against osteoporosis in the mature ovariectomized rat.
Calcif Tissue Int.
1984;
36
123-125
-
13
Vanderschueren D E, Vautterck A MH, Suiker W J, Wisser L PC, Schot R, Bouillon R.
Bone and mineral metabolism in aged male rats. Short and long term effects of androgen deficiency.
Endocrinology.
1992;
130
2906-2916
-
14
Turner C H, Burr D B.
Basic Biomechanical measurements of bone: A tutorial.
Bone.
1993;
14
595-608
-
15 Růžička R, Michálek J, Rosenkrancová J, Sedláček R. Cross section parameters acquisition from digital images. Prague; Proc. of workshop 2002, Prague CTU 2002 B: 910-911
-
16
Duncan D.
Multiple range and multiple F test.
Biometrics.
1955;
11
1-4
-
17
Compston J E.
Sex steroids and bone.
Physiol Rev.
2001;
81
419-447
-
18
Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsperg T C, Riggs B L.
Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.
Endocrinology.
1999;
140
4367-4370
-
19
Khosla S, Melton L J, Atkinson E J, O'Fallon W A, Klee G G, Riggs B L.
Relationship of serum sex steroid levels and bone turnover markers with bone density in men and women a key role for bioavailable estrogen.
J Clin Endocrin Metab.
1998;
83
2266-2274
-
20
Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, Duboeuf F, Delmas P D.
Bioavailable estradiol may be an important determinant of osteoporosis in men: The MINOS study.
J Clin Endocrinol Metab.
2001;
86
192-199
-
21
Colvard D S, Eriksen E P, Keeting P E, Wilson E M, Lubahn D B, French F S, Riggs B L, Spelberg T C.
Identification of androgen receptors in normal human osteoblast-line cells.
Proc Natl Acad Sci USA.
1989;
86
854-857
-
22
Bruch H B, Wolf L, Budde R, Romato G, Schweikert H U.
Androstenedione metabolism in cultured human osteoblast-like cells.
J Clin Endocrinol Metab.
1992;
75
101-105
-
23
Morishima A, Grumbach M M, Simpson E R, Fischer C, Qin K.
Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens.
J Clin Endocrinol Metab.
1995;
80
3689-3698
-
24
Lubahn D B, Mayer J S, Golding T S, Couse J F, Korach K S, Smithies O.
Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene.
Proc natl Acad Sci USA.
1993;
90
11 162-11 166
-
25
Smith E, Boyd J, Frank G R, Takahashi H, Cohem R M, Specker B, Williams T C, Lubahn D B, Korach K S.
Estrogen resistance caused by a mutation in the estrogen-receptor gene in man.
N Engl J med.
1994;
331
1056-1061
-
26
Vanderschueren D E, van Herck E, Nijs J, Ederveen A GH, de Coster R, Bouillon R.
Aromatase inhibition impairs skeletal modeling and decreases bone mineral density In growing male rats.
Endocrinology.
1997;
138
2301-2307
Prof. Dr. P. D. Broulik, M.D.
3rd Internal Clinic · Medical School
U nemocnice 1 · 12808 Prague 2 · Czech Republic ·
Email: pbrou@lfl.cuni.cz
